Compensation of fitness costs and reversibility of antibiotic resistance mutations

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2085-2095

  Zur Wiesch, Pia Schulz ^a   Engelstädter, Jan ^a   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; FITNESS; GENE LOCUS; GENOTYPE; NONHUMAN; PRIORITY JOURNAL; THEORETICAL MODEL; WILD TYPE;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; EVOLUTION; EXTINCTION, BIOLOGICAL; GENOTYPE; MODELS, GENETIC; MUTATION;

EID: 77951223398     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01460-09     Document Type: Article

References (85)

1. Alekshun, M. N., and S. B. Levy. 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050.
2. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6:452-456.
3. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9:461-465.
4. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493.
5. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
6. Baldwin, C., and B. Berkhout. 2007. HIV-1 drug-resistance and drug-dependence. Retrovirology 4:78.
7. Baptista, M., F. Depardieu, P. Reynolds, P. Courvalin, and M. Arthur. 1997. Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci. Mol. Microbiol. 25:93-105.
8. Bergstrom, C. T., and M. Feldgarden. 2008. The ecology and evolution of antibiotic-resistant bacteria, p. 125-137. In S. C. Stearns and J. C. Koella (ed.), Evolution in health and disease. Oxford University Press, New York, NY.
9. Besier, S., A. Ludwig, V. Brade, and T. A. Wichelhaus. 2005. Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1426-1431.
10. Bjorkholm, B., M. Sjolund, P. G. Falk, O. G. Berg, L. Engstrand, and D. I. Andersson. 2001. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc. Natl. Acad. Sci. U. S. A. 98:14607-14612.
11. Bjorkman, J., D. Hughes, and D. I. Andersson. 1998. Virulence of antibioticresistant Salmonella Typhimurium. Proc. Natl. Acad. Sci. U. S. A. 95:3949-3953.
12. Bjorkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
13. Bonhoeffer, S., M. Lipsitch, and B. R. Levin. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. U. S. A. 94:12106-12111.
14. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
15. Bottger, E. C., and B. Springer. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr. 167:141-148.
16. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277.
17. Bulitta, J. B., N. S. Ly, J. C. Yang, A. Forrest, W. J. Jusko, and B. T. Tsuji. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:46-56.
18. Campion, J. J., P. J. McNamara, and M. E. Evans. 2005. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:209-219.
19. Cirz, R. T., J. K. Chin, D. R. Andes, V. de Crecy-Lagard, W. A. Craig, and F. E. Romesberg. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176.
20. Cowen, L. E., L. M. Kohn, and J. B. Anderson. 2001. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 183:2971-2978.
21. Dethlefsen, L., S. Huse, M. L. Sogin, and D. A. Relman. 2008. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6:e280.
22. Fernebro, J., C. Blomberg, E. Morfeldt, H. Wolf-Watz, S. Normark, and B. H. Normark. 2008. The influence of in vitro fitness defects on pneumococcal ability to colonize and to cause invasive disease. BMC Microbiol. 8:65.
23. Finkel, S. E. 2006. Long-term survival during stationary phase: evolution and the GASP phenotype. Nat. Rev. Microbiol. 4:113-120.
24. Fraimow, H. S., and D. L. Jungkind. 1995. Vancomycin-dependent enterococci: a clinical and laboratory assessment. Adv. Exp. Med. Biol. 390:97-107.
25. Gerrish, P. J., and J. G. Garcia-Lerma. 2003. Mutation rate and the efficacy of antimicrobial drug treatment. Lancet Infect. Dis. 3:28-32.
26. Grant, A. J., O. Restif, T. J. McKinley, M. Sheppard, D. J. Maskell, and P. Mastroeni. 2008. Modelling within-host spatiotemporal dynamics of invasive bacterial disease. PLoS Biol. 6:e74.
27. Griffith, D., and M. N. Dudley. 2007. Animal models of infection for the study of antibiotic pharmacodynamics, p. 79-102. In C. H. Nightingale, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. CRC Press, Boca Raton, FL.
28. Guillemot, D., C. Carbon, B. Balkau, P. Geslin, H. Lecoeur, F. Vauzelle-Kervroedan, G. Bouvenot, and E. Eschwege. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279:365-370.
29. Gustafsson, I., O. Cars, and D. I. Andersson. 2003. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J. Antimicrob. Chemother. 52:258-263.
30. Hancock, R. E. 2005. Mechanisms of action of newer antibiotics for Grampositive pathogens. Lancet Infect. Dis. 5:209-218.
31. Handel, A., E. Margolis, and B. R. Levin. 2009. Exploring the role of the immune response in preventing antibiotic resistance. J. Theor. Biol. 256:655-662.
32. Handel, A., R. R. Regoes, and R. Antia. 2006. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput. Biol. 2:e137.
33. Huang, T. D., C. Almpanis, O. Denis, C. Nonhoff, B. Delaere, and Y. Glupczynski. 2007. Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate. Eur. J. Clin. Microbiol. Infect. Dis. 26:419-422.
34. Hurdle, J. G., A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra. 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob. Agents Chemother. 48:4366-4376.
35. Ihaka, R., and R. Gentleman. 1996. R: a language for data analysis and graphics. J. Comput. Graph. Stat. 5:299-314.
36. Jeger, M. J., P. J. Wijngaarden, and R. F. Hoekstra. 2008. Adaptation to the cost of resistance in a haploid clonally reproducing organism: the role of mutation, migration and selection. J. Theor. Biol. 252:621-632.
37. Jiang, H., J. J. Patel, M. Yi, J. Mu, J. Ding, R. Stephens, R. A. Cooper, M. T. Ferdig, and X. Z. Su. 2008. Genome-wide compensatory changes accompany drug-selected mutations in the Plasmodium falciparum crt gene. PLoS One 3:e2484.
38. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
39. Kimura, M. 1990. Some models of neutral evolution, compensatory evolution, and the shifting balance process. Theor. Popul. Biol. 37:150-158.
40. Komp Lindgren, P., A. Karlsson, and D. Hughes. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47:3222-3232.
41. Kondo, N., K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki, and K. Hiramatsu. 2001. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob. Agents Chemother. 45:815-824.
42. Levin, B. R. 2001. Minimizing potential resistance: a population dynamics view. Clin. Infect. Dis. 33(Suppl. 3):S161-S169.
43. Levin, B. R., V. Perrot, and N. Walker. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-997.
44. Lipsitch, M. 2001. The rise and fall of antimicrobial resistance. Trends Microbiol. 9:438-444.
45. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
46. Loewe, L., V. Textor, and S. Scherer. 2003. High deleterious genomic mutation rate in stationary phase of Escherichia coli. Science 302:1558-1560.
47. Lofmark, S., C. Jernberg, H. Billstrom, D. I. Andersson, and C. Edlund. 2008. Restored fitness leads to long-term persistence of resistant Bacteroides strains in the human intestine. Anaerobe 14:157-160.
48. Luo, N., S. Pereira, O. Sahin, J. Lin, S. Huang, L. Michel, and Q. Zhang. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. U. S. A. 102:541-546.
49. Ma, C., J. Tran, C. Li, L. Ganesan, D. Wood, and N. Morrissette. 2008. Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations. Genetics 180:845-856.
50. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155:360-369.
51. Majcherczyk, P. A., J. L. Barblan, P. Moreillon, and J. M. Entenza. 2008. Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis. Microb. Pathog. 45:408-414.
52. Marcusson, L. L., N. Frimodt-Moller, and D. Hughes. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541.
53. Martinez, J. L., and F. Baquero. 2000. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:1771-1777.
54. May, R. M. 1976. Simple mathematical models with very complicated dynamics. Nature 261:459-467.
55. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48:2061-2068.
56. Meka, V. G., H. S. Gold, A. Cooke, L. Venkataraman, G. M. Eliopoulos, R. C. Moellering, Jr., and S. G. Jenkins. 2004. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J. Antimicrob. Chemother. 54:818-820.
57. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
58. Na, H. S., H. J. Kim, H. C. Lee, Y. Hong, J. H. Rhee, and H. E. Choy. 2006. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine 24:2027-2034.
59. Needham, A. J., M. Kibart, H. Crossley, P. W. Ingham, and S. J. Foster. 2004. Drosophila melanogaster as a model host for Staphylococcus aureus infection. Microbiology 150:2347-2355.
60. Nijhuis, M., S. Deeks, and C. Boucher. 2001. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14:23-28.
61. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 blood-stream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
62. Pakyz, A. L., M. Oinonen, and R. E. Polk. 2009. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:1983-1986.
63. Paulander, W., S. Maisnier-Patin, and D. I. Andersson. 2007. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium. Mol. Microbiol. 64:1038-1048.
64. Perichon, B., and P. Courvalin. 2009. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4580-4587.
65. Peters, R. P., M. A. van Agtmael, S. Gierveld, S. A. Danner, A. B. Groeneveld, C. M. Vandenbroucke-Grauls, and P. H. Savelkoul. 2007. Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in the intensive care unit. J. Clin. Microbiol. 45:3641-3646.
66. Randall, L. P., M. C. Bagnall, K. A. Karatzas, N. C. Coldham, L. J. Piddock, and M. J. Woodward. 2008. Fitness and dissemination of disinfectant-selected multiple-antibiotic-resistant (MAR) strains of Salmonella enterica serovar Typhimurium in chickens. J. Antimicrob. Chemother. 61:156-162.
67. Reynolds, M. G. 2000. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156:1471-1481.
68. Rozen, D. E., L. McGee, B. R. Levin, and K. P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:412-416.
69. Ruusala, T., D. Andersson, M. Ehrenberg, and C. G. Kurland. 1984. Hyperaccurate ribosomes inhibit growth. EMBO J. 3:2575-2580.
70. Saager, B., H. Rohde, B. S. Timmerbeil, G. Franke, W. Pothmann, J. Dahlke, S. Scherpe, I. Sobottka, P. Heisig, and M. A. Horstkotte. 2008. Molecular characterisation of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using pyrosequencing. Eur. J. Clin. Microbiol. Infect. Dis. 27:873-878.
71. San Millan, A., F. Depardieu, S. Godreuil, and P. Courvalin. 2009. VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin. Antimicrob. Agents Chemother. 53:1974-1982.
72. Schoustra, S. E., A. J. Debets, M. Slakhorst, and R. F. Hoekstra. 2006. Reducing the cost of resistance; experimental evolution in the filamentous fungus Aspergillus nidulans. J. Evol. Biol. 19:1115-1127.
73. Schrag, S. J., V. Perrot, and B. R. Levin. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. Biol. Sci. 264:1287-1291.
74. Sniegowski, P. 2004. Evolution: bacterial mutation in stationary phase. Curr. Biol. 14:R245-R246.
75. Sommer, M. O., G. Dantas, and G. M. Church. 2009. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325:1128-1131.
76. Strauss, O. J., R. M. Warren, A. Jordaan, E. M. Streicher, M. Hanekom, A. A. Falmer, H. Albert, A. Trollip, E. Hoosain, P. D. van Helden, and T. C. Victor. 2008. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 46:1514-1516.
77. Tam, V. H., S. Kabbara, G. Vo, A. N. Schilling, and E. A. Coyle. 2006. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:2626-2631.
78. Udekwu, K. I., N. Parrish, P. Ankomah, F. Baquero, and B. R. Levin. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
79. Van Bambeke, F., M. Chauvel, P. E. Reynolds, H. S. Fraimow, and P. Courvalin. 1999. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Antimicrob. Agents Chemother. 43:41-47.
80. Wilson, M. L., and L. Gaido. 2004. Laboratory diagnosis of urinary tract infections in adult patients. Clin. Infect. Dis. 38:1150-1158.
81. Wolter, N., A. M. Smith, D. J. Farrell, and K. P. Klugman. 2006. Heterogeneous macrolide resistance and gene conversion in the pneumococcus. Antimicrob. Agents Chemother. 50:359-361.
82. World Health Organization, T. Prentice, and L. Tucker Reinders. 2007. The world health report 2007 - a safer future: global public health security in the 21st century. World Health Organization, Geneva, Switzerland.
83. Wright, S. 1982. The shifting balance theory and macroevolution. Annu. Rev. Genet. 16:1-19.
84. Yeh, P. J., M. J. Hegreness, A. P. Aiden, and R. Kishony. 2009. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7:460-466.
85. Zhang, Q., O. Sahin, P. F. McDermott, and S. Payot. 2006. Fitness of antimicrobial-resistant Campylobacter and Salmonella. Microbes Infect. 8:1972-1978.